MedTrace Logo

An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis

NCT00826514 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2021-05-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether tanezumab is effective in the treatment of pain associated with chronic prostatitis.

Conditions

  • Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Interventions

DRUG

Tanezumab

Intravenous, 20 mg, single dose.

DRUG

Placebo

Intravenous placebo, single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-25
Primary Completion
2010-01-11
Completion
2010-03-17

Countries

  • United States
  • Canada
  • France
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00826514 on ClinicalTrials.gov